Clinical Trials
34 trialsNCT02493530 2026-05-19
TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to Hydroxyurea
Vanderbilt-Ingram Cancer Center
Phase 1 Completed
NCT03269669 2026-05-13
Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT03919175 2026-02-27
Umbralisib and Rituximab as Initial Therapy for Patients With Follicular Lymphoma and Marginal Zone Lymphoma
Massachusetts General Hospital
Phase 2 Terminated
NCT04624633 2026-02-25
Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLL
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT04163718 2026-01-06
TGR-1202 (Umbralisib) in Treatment Naïve Patients With Chronic Lymphocytic Leukemia (CLL)
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Terminated
NCT03283137 2025-02-07
Combination of Pembrolizumab With TGR-1202 in Patients With Relapsed/Refractory CLL and B-cell NHL
University of Chicago
Phase 1 Active not recruiting
NCT02612311 2024-12-13
UNITY-CLL
TG Therapeutics, Inc.
Phase 3 Terminated
NCT04783415 2024-12-02
Acalabrutinib, Umbralisib, and Ublituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma
City of Hope Medical Center
Phase 2 Active not recruiting
NCT02268851 2024-11-15
A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCL
Dana-Farber Cancer Institute
Phase 1 Completed
NCT03671590 2024-07-19
Study of TG-1701, an Irreversible Bruton's Tyrosine Kinase Inhibitor, in Patients With B-Cell Malignancies
TG Therapeutics, Inc.
Phase 1 Terminated
NCT02742090 2024-07-03
Evaluate the Efficacy and Safety of TGR-1202 in Participants With Chronic Lymphocytic Leukemia Who Are Intolerant to Prior Therapy
TG Therapeutics, Inc.
Phase 2 Terminated
NCT03801525 2024-04-19
ULTRA-V
TG Therapeutics, Inc.
Phase 2/3 Terminated
NCT04508647 2024-03-21
Ublituximab Followed by Response-driven Addition of Umbralisib for Treatment-naive Follicular or Marginal Zone Lymphoma
University of Colorado, Denver
Phase 2 Completed
NCT02874404 2023-10-05
TGR-1202 and Ibrutinib in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
University of Nebraska
Phase 2 Completed
NCT04692155 2023-09-28
CHOP U2
University of Alabama at Birmingham
Phase 1/2 Terminated
NCT03828448 2023-07-24
Study to Assess Umbralisib Plus Ublituximab in Participants With Treatment Naïve Follicular Lymphoma
TG Therapeutics, Inc.
Phase 2 Terminated
NCT04016805 2023-07-24
Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Participants With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib, Acalabrutinib or Venetoclax
TG Therapeutics, Inc.
Phase 2 Terminated
NCT03364231 2023-06-23
Study to Assess the Efficacy and Safety of Umbralisib in Participants With Non-Follicular Indolent Non-Hodgkin's Lymphoma
TG Therapeutics, Inc.
Phase 2 Completed
NCT02656303 2023-06-22
A Study to Evaluate the Safety and Efficacy of Ublituximab in Combination With Umbralisib for Participants Previously Enrolled in Protocol UTX-TGR-304
TG Therapeutics, Inc.
Phase 2 Terminated
NCT04149821 2023-06-15
Umbralisib Plus Ublituximab (U2) in Progressive CLL After Novel Therapy
Weill Medical College of Cornell University
Phase 2 Terminated
NCT05152459 2023-05-31
Tazemetostat in Combination With Umbralisib and Ublituximab for the Treatment Relapsed or Refractory Follicular Lymphoma
City of Hope Medical Center
Phase 1/2 Withdrawn
NCT03776864 2023-05-03
Umbralisib and Pembrolizumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
University of Washington
Phase 2 Terminated
NCT02535286 2022-10-20
Study of Immunotherapy in Combination With Ublituximab and Umbralisib in Patients With Relapsed-refractory CLL or Richter's Transformation
TG Therapeutics, Inc.
Phase 1 Completed
NCT04635683 2022-09-30
Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma
Ohio State University Comprehensive Cancer Center
Phase 1 Withdrawn
NCT03379051 2022-08-22
Phase I/II Study of Venetoclax or Lenalidomide in Combination With Ublituximab and Umbralisib in Subjects With Relapsed or Refractory CLL/SLL and NHL
TG Therapeutics, Inc.
Phase 1/2 Terminated
NCT02793583 2022-07-21
UNITY-NHL
TG Therapeutics, Inc.
Phase 2/3 Terminated
NCT03207256 2022-07-21
Extension Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in Subjects Currently Receiving Treatment on Ublituximab and/or TGR-1202 Trials
TG Therapeutics, Inc.
Phase 2 Terminated
NCT01767766 2021-08-23
Evaluate the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic Malignancies
TG Therapeutics, Inc.
Phase 1 Completed
NCT02867618 2021-07-16
Carfilzomib and TGR-1202 in Treatment of R/R Lymphoma
Columbia University
Phase 1/2 Terminated
NCT03178201 2021-07-16
TGR1202 in Relapsed and Refractory Follicular Lymphoma
Columbia University
Phase 2 Terminated
NCT02006485 2019-11-05
Ublituximab in Combination With TGR-1202 +/- Ibrutinib or Bendamustine in Patients With B-cell Malignancies
TG Therapeutics, Inc.
Phase 1 Completed
NCT02100852 2019-10-02
TGR-1202, a PI3K Delta Inhibitor, in Combination With Obinutuzumab and Chlorambucil in Patients With Chronic Lymphocytic Leukemia (CLL)
TG Therapeutics, Inc.
Phase 1 Completed
NCT02164006 2019-10-02
Novel PI3K Delta Inhibitor TGR-1202, in Combination With Brentuximab Vedotin for Hodgkin's Lymphoma Patients
TG Therapeutics, Inc.
Phase 1 Completed
NCT02574663 2019-10-02
TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors
TG Therapeutics, Inc.
Phase 1 Completed